Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients

The major concern regarding the use of low-dose oral minoxidil (LDOM) for the treatment of hair loss is the potential risk of systemic adverse effects. To describe the safety of LDOM for the treatment of hair loss in a large cohort of patients. Retrospective multicenter study of patients treated wit...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of the American Academy of Dermatology Vol. 84; no. 6; pp. 1644 - 1651
Main Authors:	Vañó-Galván, Sergio, Pirmez, Rodrigo, Hermosa-Gelbard, Angela, Moreno-Arrones, Óscar M., Saceda-Corralo, David, Rodrigues-Barata, Rita, Jimenez-Cauhe, Juan, Koh, Wei L., Poa, Janina E., Jerjen, Rebekka, Trindade de Carvalho, Lara, John, Jared Marc, Salas-Callo, Corina I., Vincenzi, Colombina, Yin, Lu, Lo-Sicco, Kristen, Waskiel-Burnat, Anna, Starace, Michela, Zamorano, Jose Luis, Jaén-Olasolo, Pedro, Piraccini, Bianca Maria, Rudnicka, Lidia, Shapiro, Jerry, Tosti, Antonella, Sinclair, Rodney, Bhoyrul, Bevin
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01-06-2021
Subjects:	alopecia androgenetic alopecia arterial hypotension dizziness edema effluvium fluid retention frontal fibrosing alopecia hair loss hypertrichosis lichen planopilaris lightheadedness new treatments periorbital edema safety tachycardia dizziness edema frontal fibrosing alopecia new treatments fluid retention hair loss arterial hypotension hypertrichosis periorbital edema alopecia LDOM safety tachycardia EOD lichen planopilaris lightheadedness androgenetic alopecia effluvium
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The major concern regarding the use of low-dose oral minoxidil (LDOM) for the treatment of hair loss is the potential risk of systemic adverse effects. To describe the safety of LDOM for the treatment of hair loss in a large cohort of patients. Retrospective multicenter study of patients treated with LDOM for at least 3 months for any type of alopecia. A total of 1404 patients (943 women [67.2%] and 461 men [32.8%]) with a mean age of 43 years (range 8-86) were included. The dose of LDOM was titrated in 1065 patients, allowing the analysis of 2469 different cases. The most frequent adverse effect was hypertrichosis (15.1%), which led to treatment withdrawal in 14 patients (0.5%). Systemic adverse effects included lightheadedness (1.7%), fluid retention (1.3%), tachycardia (0.9%), headache (0.4%), periorbital edema (0.3%), and insomnia (0.2%), leading to drug discontinuation in 29 patients (1.2%). No life-threatening adverse effects were observed. Retrospective design and lack of a control group. LDOM has a good safety profile as a treatment for hair loss. Systemic adverse effects were infrequent and only 1.7% of patients discontinued treatment owing to adverse effects.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0190-9622 1097-6787
DOI:	10.1016/j.jaad.2021.02.054